Genocea to Present at the ESMO Virtual Congress and Two Investor Conferences in September
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the company will present incremental follow-up data, including additional tumor scan results and detailed immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2 a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. Genocea expects to share similar clinical and immunogenicity data from the remaining 10 Part B patients later this year.
| Conferences Details: | |||
| Event: | European Society for Medical Oncology (ESMO) Virtual Congress 2020 | ||
| Format: | Poster 1028P and Abstract #3549; Preliminary results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumor specific neoantigens, in combination with PD-1 inhibitors in advanced cancers | ||
| Date: | Thursday, September 17TH | ||
| Time: | 9:00 a.m. CEST (3.00 a.m. ET) | ||
| In addition, Chip Clark, president and chief executive officer, will present via webcast corporate overviews at the virtual Baird Global Healthcare Conference and the virtual H.C. Wainwright 22nd Annual Global Investment Conference. | |||
| Conferences Details: | |||
| Event: | Baird Global Healthcare Conference 2020 (virtual) | ||
| Format: | Presentation | ||
| Date: | Thursday, September 10TH | ||
| Time: | 4:20 p.m. ET | ||
| Event: | H.C. Wainwright 22nd Annual Global Investment Conference (virtual) | ||
| Format: | Presentation | ||
| Date: | Tuesday, September 15TH | ||
| Time: | 1:30 p.m. ET | ||
Live webcasts of these presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at . Replays of the webcasts will be archived for 90 days following the conferences.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we expect to conduct a Phase 1/2a clinical trial. To learn more, please visit .
Forward-Looking Statements
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
Investor Contact:
Dan Ferry
617-430-7576
